Literature DB >> 2914642

Hapten-induced model of chronic inflammation and ulceration in the rat colon.

G P Morris1, P L Beck, M S Herridge, W T Depew, M R Szewczuk, J L Wallace.   

Abstract

We have developed a simple and reproducible rat model of chronic colonic inflammation by the intraluminal instillation of a solution containing a "barrier breaker" and a hapten. Administration of the hapten 2,4,6-trinitrobenzenesulfonic acid (5-30 mg) in 0.25 ml of 50% ethanol as the "barrier breaker" produced dose-dependent colonic ulceration and inflammation. At a dose of 30 mg, trinitrobenzenesulfonic acid/ethanol-induced ulceration and marked thickening of the bowel wall persisted for at least 8 wk. Histologically, the inflammatory response included mucosal and submucosal infiltration by polymorphonuclear leukocytes, macrophages, lymphocytes, connective tissue mast cells, and fibroblasts. Granulomas were observed in 57% of the rats killed 3 wk after induction of inflammation. Langhan's-type giant cells were also observed. Segmental ulceration and inflammation were common. The characteristics and relatively long duration of inflammation and ulceration induced in this model afford an opportunity to study the pathophysiology of colonic inflammatory disease in a specifically controlled fashion, and to evaluate new treatments potentially applicable to inflammatory bowel disease in humans.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2914642

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  516 in total

1.  Molecular basis of altered contractility in experimental colitis: expression of L-type calcium channel.

Authors:  I Khan
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

2.  Temporal patterns of colonic blood flow and tissue damage in an animal model of colitis.

Authors:  C B Appleyard; J L Williams; C A Hathaway; W H Percy
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

3.  Beneficial effects of glycocholic acid (GCA) on gut mucosal damage in bile duct ligated rats.

Authors:  B K Oktar; M A Gülpinar; F Ercan; A Cingi; I Alican; B C Yegen
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

4.  Calpain inhibitor I and colonic inflammation induced by DNBS in the rat.

Authors:  A Ballinger; O Azooz
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

5.  Expression of interleukin 6 in brain and colon of rats with TNBS-induced colitis.

Authors:  Kai Wang; Chuan-Ping Yuan; Wei Wang; Zhan-Qing Yang; Wei Cui; Lian-Zhi Mu; Zhan-Peng Yue; Xiu-Ling Yin; Zhong-Ming Hu; Ju-Xiong Liu
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

6.  Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis.

Authors:  Jan Seibel; Almut F Molzberger; Torsten Hertrampf; Ute Laudenbach-Leschowski; Patrick Diel
Journal:  Eur J Nutr       Date:  2009-02-21       Impact factor: 5.614

7.  Compromised neuroimmune status in rats with experimental colitis.

Authors:  Lysa Boissé; Marja D Van Sickle; Keith A Sharkey; Quentin J Pittman
Journal:  J Physiol       Date:  2003-03-14       Impact factor: 5.182

8.  Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats.

Authors:  T G Moreels; R J Nieuwendijk; J G De Man; B Y De Winter; A G Herman; E A Van Marck; P A Pelckmans
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Indomethacin and retinoic acid modify mouse intestinal inflammation and fibrosis: a role for SPARC.

Authors:  Borut Klopcic; Amber Appelbee; Warren Raye; Frances Lloyd; James C I Jooste; Cynthia Heather Forrest; Ian Craig Lawrance
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

10.  Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis.

Authors:  Jörn Karhausen; Glenn T Furuta; John E Tomaszewski; Randall S Johnson; Sean P Colgan; Volker H Haase
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.